- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
2023 AUA preview: Dr. Li on top research in bladder cancer
Roger Li, MD, highlights 4 studies in bladder cancer being presented at the 2023 American Urological Association Annual Meeting.
EP: 1.2023 AUA preview: Dr. Cookson on top research in prostate cancer
EP: 2.2023 AUA preview: Dr. Bernie on top research in sexual dysfunction
EP: 3.2023 AUA preview: Dr. Laudano on top research in overactive bladder/incontinence
EP: 4.2023 AUA preview: Dr. Li on top research in bladder cancer
In this video, Roger Li, MD, discusses 4 studies in bladder cancer being presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Li is a urologic oncologist at Moffitt Cancer Center in Tampa, Florida.
The following abstracts were previewed:
1. LBA02-08 (Milowsky et al): Results from the extended follow-up in patients with muscle-invasive bladder cancer in the CheckMate 274 trial
2. LBA03-08 (Singer et al): Pembrolizumab (pembro) for patients (pts) with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Efficacy and evaluation of subsequent cystectomy from cohort B of the phase 2 KEYNOTE-057 study
3. LBA02-03 (Daneshmand et al): First results from SunRISE-1 in patients with BCG unresponsive high-risk non-muscle-invasive bladder cancer receiving TAR-200 in combination with cetrelimab, TAR-200, or cetrelimab alone
4. PD13-08 (Li et al): CORE1: Phase 2 single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin (BCG)
